Azenta earnings release, August 4, 2026
Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.
BURLINGTON, Mass., August 4, 2026 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026.
The results of B Medical Systems are reported as discontinued operations and reflected in total diluted EPS. The Company entered into a definitive agreement to sell the business during fiscal 2025, and the transaction closed on July 1, 2026, on the terms described in the Company’s Current Report on Form 8-K filed on July 8, 2026.
(1)
Reflects revisions for an immaterial classification error among cost of revenue, research and development expenses, and selling, general and administrative expenses, and other immaterial adjustments, as further described in the Annual Report on Form 10-K for the fiscal year ended September 30, 2025.
Management Comments
"Despite an uneven and challenging market backdrop, our third quarter results exceeded our expectations, with continued strength in our recurring revenue businesses, and a modest improvement in Multiomics in North America," said John Marotta, President and Chief Executive Officer. "While these results represent an encouraging step forward, our turnaround continues, and we remain focused on executing against our strategic priorities."
Third Quarter Fiscal 2026 Results - Continuing Operations
• Revenue was $161 million, up 12% year over year. Organic revenue, which excludes a 1-percentage point impact from foreign exchange and a 3-percentage point impact from the acquisition of UK Biocentre Limited, was up 9% year over year, reflecting higher revenue in Sample Management Solutions and Multiomics.
• Sample Management Solutions revenue was $88 million, up 14% year over year.¹
◦ Organic revenue, which excludes the impact from foreign exchange and the contribution from the acquisition of UK Biocentre Limited, was up 9%, mainly driven by higher revenue in Sample Repository Solutions and Consumables and Instruments, partially offset by lower revenue in Automated Stores.
• Multiomics revenue was $73 million, up 10% year over year.
◦ Organic revenue, which excludes the impact from foreign exchange, was up 8% year over year, primarily driven by higher revenue in Next Generation Sequencing and Gene Synthesis, partially offset by lower Sanger Sequencing revenue.
Summary of GAAP Earnings Results - Continuing Operations
• Operating loss was $4.2 million. Operating margin was (2.6%), down 131 basis points year over year.
◦ Gross margin was 44.9%, a decrease of 130 basis points year over year, primarily driven by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio as well as costs related to quality remediation and rework activities in Automated Stores. These impacts were partially offset by improved operating leverage and the benefits of ongoing cost initiatives.
◦ Operating expenses in the quarter were $77 million, up 12% year over year, driven by higher research and development expenses and higher selling, general and administrative expenses, partially offset by lower restructuring and transformation charges.
• Total other income included $4 million of net interest income, versus $5 million in the prior year period.
• Diluted EPS from continuing operations was ($0.03) compared to ($0.01) in the third quarter of fiscal year 2025. Diluted EPS from discontinued operations was $0.09, compared to ($1.04) a year ago. Total diluted EPS was $0.05, compared to ($1.05) a year ago.
Summary of Non-GAAP Earnings Results - Continuing Operations
• Adjusted operating income was $4.7 million. Adjusted operating margin was 2.9%, a decrease of 180 basis points year over year.
◦ Adjusted gross margin was 46.2%, down 140 basis points compared to the third quarter of fiscal 2025, primarily driven by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio as well as costs related to quality remediation and rework activities in Automated Stores. These impacts were partially offset by improved operating leverage and the benefits of ongoing cost initiatives.
◦ Adjusted operating expenses in the quarter were $70 million, up 13% year over year, driven by higher selling, general and administrative expenses and higher research and development expenses.
• Adjusted EBITDA was $18.5 million, and Adjusted EBITDA margin was 11.4%, a decrease of 60 basis points year over year.
• Non-GAAP Diluted EPS was $0.16, compared to $0.17 one year ago.
Cash and Liquidity as of June 30, 2026
• The Company ended the quarter with a total balance of cash, cash equivalents, restricted cash and marketable securities of $529 million.
• Operating cash flow was $1 million in the quarter. Capital expenditures were $7 million, and free cash flow (cash flow from operations less capital expenditures) was negative $5 million.
Share Repurchase Program Update
• On December 8, 2025, our Board of Directors approved a share repurchase program authorizing the repurchase of up to $250 million of our common stock through December 31, 2028, or the 2025 Repurchase Program. Repurchases under the 2025 Repurchase Program may be made in the open market or through privately negotiated transactions (including under an accelerated share repurchase agreement), or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act, subject to market and business conditions, legal requirements, and other factors. As of June 30, 2026, the Company repurchased 2.3 million shares of common stock for $50.0 million (excluding fees, commissions, and excise tax) pursuant to the 2025 Repurchase Program. All shares of common stock repurchased under the 2025 Repurchase Program have been retired.²
Fourth Quarter Fiscal 2026 Guidance - Continuing Operations
• ... (truncated)e acquisition of UK Biocentre Limited, is expected to decline approximately in the low single digits relative to the fourth quarter of fiscal 2025.
• Adjusted EBITDA is expected to range approximately between $20 million and $23 million.
Full Year Fiscal 2026 Guidance - Continuing Operations
The Company now expects total reported revenue from continuing operations to range approximately between $613 to $618 million, compared to prior guidance of $603 to $621 million for the fiscal year ending September 30, 2026.
• Total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is now expected to range approximately between flat to up 1%, compared to prior guidance of down 2% to up 1% relative to fiscal 2025.
◦ Organic revenue for Sample Management Solutions is expected to grow low-single-digits, consistent with prior guidance.
◦ Organic revenue for Multiomics is now expected to range approximately between down 1% to flat, compared to prior guidance of down mid-single-digits.
• Adjusted EBITDA is expected to be in the range of $59 million to $62 million, including an anticipated impact of approximately 30 basis points of margin dilution from the UK Biocentre acquisition.
• Free cash flow (cash flow from operations less capital expenditures) is expected to improve approximately 10% to 15% year-over-year, consistent with prior guidance.
Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures, governance-related matters, goodwill and intangible impairments, stock-based compensation, and other gains and charges that are not representative of the normal operations of the business.
Conference Call and Webcast
Azenta management will webcast its third quarter fiscal 2026 earnings conference call on August 5, 2026 at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.
The call will be broadcast live over the Internet and, together with presentation materials and supplemental information referenced on the call, will be hosted at the Investor Relations section of Azenta’s website at https://investors.azenta.com/events. The supplemental information is being posted at the time of this earnings release, and the presentation materials will be posted ahead of the earnings call. A replay of the webcast will be archived on the website for convenient on-demand access.
Regulation G – Use of Non-GAAP Financial Measures
This release includes non-GAAP financial measures, including organic revenue, adjusted gross profit and margin, adjusted operating income, expenses and margin, EBITDA, Adjusted EBITDA and Adjusted EBITDA margin, non-GAAP net income, non-GAAP diluted EPS and free cash flow. Management believes these measures give investors additional insight into the results of business operations, improve period-to-period comparability and facilitate comparison with peers. Management uses these measures to evaluate business performance and uses organic revenue (referred to as Core Revenue in the Company’s proxy statement), Adjusted EBITDA and free cash flow in determining compensation under the Company’s annual incentive plan. They are not presented in accordance with, and are not a substitute for, U.S. generally accepted accounting principles, or GAAP, should always be considered together with the most directly comparable GAAP measures, and may not be comparable to similarly titled measures used by other companies. These measures are presented on a continuing operations basis, except free cash flow, which is presented on a total company basis inclusive of B Medical Systems. Non-GAAP diluted EPS does not exclude stock-based compensation; the Company separately presents non-GAAP adjusted net income excluding stock-based compensation. Reconciliations to the most directly comparable GAAP measures, and descriptions of the adjustments, are included at the end of this release under “Notes on Non-GAAP Financial Measures.” Certain amounts may not sum due to rounding, and all percentages are calculated using unrounded amounts.³
“Safe Harbor Statement” under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended
S... (truncated)nal, commercial and organizational transformation initiatives; anticipated productivity improvements and cost actions; expectations regarding demand trends and end market conditions; statements regarding the Company’s long range plan and multi-year financial targets, including the extension of the long range plan timeline to 2029.
Factors that could cause actual results to differ materially from those expressed or implied by forward looking statements include, but are not limited to: the Company’s ability to execute on and realize the expected benefits from its transformation and operational improvement initiatives; changes in customer demand, purchasing behavior or funding conditions in the markets the Company serves; macroeconomic, geopolitical or regulatory developments; the impact of foreign currency fluctuations; the Company’s ability to effectively manage costs, improve productivity and achieve anticipated margin improvements; supply chain disruptions; competitive dynamics; the ability of customers to meet payment obligations; risks relating to the collectability and timely repayment of the $35 million secured vendor loan extended to the buyer in connection with the B Medical Systems divestiture, including the buyer's ability to obtain permanent financing, the sufficiency of the collateral securing the loan, and the potential for an associated charge or impairment; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10 K, Quarterly Reports on Form 10 Q and Current Reports on Form 8 K. Because forward looking statements relate to future events and are based on current expectations, they are inherently subject to significant uncertainties, particularly with respect to projections and assumptions extending over multiple years. As a result, actual outcomes may differ materially from those projected.
Financial statements
Income Statement
Quarter Ended (in millions)
| Quarter Ended – June 30, – 2026 | Quarter Ended – March 31, – 2026 | Quarter Ended – June 30, – 2025(1) | Quarter Ended – Change – Prior Qtr | Quarter Ended – Change – Prior Yr. | |
|---|---|---|---|---|---|
| Revenue from Continuing Operations | 161 | 145 | 144 | 11 | 12 |
| Organic growth | 9 | ||||
| Sample Management Solutions | 88 | 81 | 78 | 9 | 14 |
| Multiomics | 73 | 64 | 66 | 14 | 10 |
| Diluted EPS Continuing Operations | -0.03 | -3.41 | -0.01 | 99 | NM |
| Diluted EPS Total | 0.05 | -3.49 | -1.05 | NM | NM |
| Non-GAAP Diluted EPS Continuing Operations | 0.16 | -0.04 | 0.17 | NM | -6 |
| Adjusted EBITDA - Continuing Operations | 18 | 8 | 17 | NM | 6 |
| Adjusted EBITDA Margin - Continuing Operations | 11.4% | 5.4% | 12.1% |
Income Statement
Three Months Ended June 30, — (In thousands, except per share data)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Nine Months Ended June 30, – 2026 | Nine Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Revenue | Products | 41,259 | 39,387 | 119,985 | 125,169 |
| Revenue | Services | 119,919 | 104,468 | 334,630 | 309,460 |
| Revenue | Total revenue | 161,178 | 143,855 | 454,615 | 434,629 |
| Cost of revenue | Products | 25,018 | 19,572 | 71,889 | 68,607 |
| Cost of revenue | Services | 63,804 | 57,879 | 184,629 | 168,016 |
| Cost of revenue | Total cost of revenue | 88,822 | 77,451 | 256,518 | 236,623 |
| Cost of revenue | Gross profit | 72,356 | 66,404 | 198,097 | 198,006 |
| Operating expenses | Research and development | 8,853 | 7,417 | 27,475 | 22,132 |
| Operating expenses | Selling, general and administrative | 67,168 | 60,083 | 195,666 | 199,854 |
| Operating expenses | Impairment of goodwill and intangible assets | 149,083 | |||
| Operating expenses | Restructuring charges | 513 | 754 | 3,078 | 4,765 |
| Operating expenses | Total operating expenses | 76,534 | 68,254 | 375,302 | 226,751 |
| Operating expenses | Operating loss | -4,178 | -1,850 | -177,205 | -28,745 |
| Other income (expense) | Interest income, net | 3,825 | 4,973 | 13,310 | 13,760 |
| Other income (expense) | Other income (expense), net | 1,199 | -820 | 5,337 | 1,542 |
| Other income (expense) | Income (loss) from continuing operations before income taxes | 846 | 2,303 | -158,558 | -13,443 |
| Other income (expense) | Income tax expense | 2,375 | 2,635 | 5,182 | 13,752 |
| Other income (expense) | Loss from continuing operations | -1,529 | -332 | -163,740 | -27,195 |
| Other income (expense) | Income (loss) from discontinued operations, net of tax | 3,985 | -47,655 | -10,034 | -79,445 |
| Other income (expense) | Net income (loss) | 2,456 | -47,987 | -173,774 | -106,640 |
| Basic net income (loss) per share: | Loss from continuing operations | -0.03 | -0.01 | -3.58 | -0.59 |
| Basic net income (loss) per share: | Income (loss) from discontinued operations, net of tax | 0.09 | -1.04 | -0.22 | -1.74 |
| Basic net income (loss) per share: | Basic net income (loss) per share | 0.05 | -1.05 | -3.8 | -2.33 |
| Diluted net income (loss) per share: | Loss from continuing operations | -0.03 | -0.01 | -3.58 | -0.59 |
| Diluted net income (loss) per share: | Income (loss) from discontinued operations, net of tax | 0.09 | -1.04 | -0.22 | -1.74 |
| Diluted net income (loss) per share: | Diluted net income (loss) per share | 0.05 | -1.05 | -3.8 | -2.33 |
| Weighted average shares used in computing net income (loss) per share: | Basic | 45,286 | 45,780 | 45,759 | 45,712 |
| Weighted average shares used in computing net income (loss) per share: | Diluted | 45,286 | 45,780 | 45,759 | 45,712 |
Income Statement
Quarter Ended (in thousands)
| Quarter Ended – June 30, 2026 – $ | Quarter Ended – June 30, 2026 – per diluted share | Quarter Ended – March 31, 2026 – $ | Quarter Ended – March 31, 2026 – per diluted share | Quarter Ended – June 30, 2025(*) – $ | Quarter Ended – June 30, 2025(*) – per diluted share | ||
|---|---|---|---|---|---|---|---|
| Net loss from continuing operations | -1,529 | -0.03 | -157,021 | -3.41 | -332 | -0.01 | |
| Adjustments: | Amortization of completed technology | 2,082 | 0.05 | 2,076 | 0.05 | 2,068 | 0.05 |
| Adjustments: | Amortization of other intangible assets | 3,616 | 0.08 | 3,563 | 0.08 | 4,123 | 0.09 |
| Adjustments: | Transformation costs(1) | 272 | 0.01 | 440 | 0.01 | 1,542 | 0.03 |
| Adjustments: | Restructuring charges | 513 | 0.01 | 1,422 | 0.03 | 754 | 0.02 |
| Adjustments: | Impairment of goodwill and intangible assets(2) | 149,083 | 3.24 | ||||
| Adjustments: | Merger and acquisition costs(3) | 2,248 | 0.05 | 2,175 | 0.05 | 58 | 0 |
| Adjustments: | Non-recurring other adjustments(4) | 0 | -3,858 | -0.08 | 38 | 0 | |
| Adjustments: | Purchase accounting adjustments | 154 | 0 | ||||
| Adjustments: | Tax effect of adjustments | -198 | 0 | 331 | 0.01 | -534 | -0.01 |
| Adjustments: | Other adjustments | 13 | 0 | ||||
| Adjustments: | Non-GAAP adjusted net income (loss) from continuing operations | 7,158 | 0.16 | -1,776 | -0.04 | 7,717 | 0.17 |
| Adjustments: | Stock-based compensation, pre-tax | 4,692 | 0.1 | 6,268 | 0.14 | 3,045 | 0.07 |
| Adjustments: | Tax rate | 13 | 13 | 17 | |||
| Adjustments: | Stock-based compensation, net of tax | 4,082 | 0.09 | 5,453 | 0.12 | 2,536 | 0.06 |
| Adjustments: | Non-GAAP adjusted net income excluding stock-based compensation - continuing operations | 11,240 | 0.25 | 3,677 | 0.08 | 10,253 | 0.22 |
| Adjustments: | Shares used in computing non-GAAP diluted net income per share | 45,286 | 46,063 | 45,780 |
Income Statement
Nine Months Ended (in thousands)
| Nine Months Ended – June 30, 2026 – $ | Nine Months Ended – June 30, 2026 – per diluted share | Nine Months Ended – June 30, 2025(*) – $ | Nine Months Ended – June 30, 2025(*) – per diluted share | ||
|---|---|---|---|---|---|
| Net loss from continuing operations | -163,740 | -3.58 | -27,195 | -0.59 | |
| Adjustments: | Amortization of completed technology | 6,017 | 0.13 | 5,876 | 0.13 |
| Adjustments: | Amortization of other intangible assets | 10,730 | 0.23 | 12,499 | 0.27 |
| Adjustments: | Transformation costs(1) | 1,913 | 0.04 | 9,771 | 0.21 |
| Adjustments: | Restructuring charges | 3,078 | 0.07 | 4,765 | 0.1 |
Income Statement
Quarter Ended (in thousands)
| Quarter Ended – June 30, 2026 | Quarter Ended – March 31, 2026 | Quarter Ended – June 30, 2025(*) | Nine Months Ended – June 30, 2026 | Nine Months Ended – June 30, 2025(*) | ||
|---|---|---|---|---|---|---|
| GAAP net loss | 2,456 | -160,798 | -47,987 | -173,774 | -106,640 | |
| Less: Loss from discontinued operations | 3,985 | -3,777 | -47,655 | -10,034 | -79,445 | |
| GAAP net loss from continuing operations | -1,529 | -157,021 | -332 | -163,740 | -27,195 | |
| Adjustments: | Interest income, net | -3,825 | -4,387 | -4,973 | -13,310 | -13,760 |
| Adjustments: | Income tax expense | 2,375 | -323 | 2,635 | 5,182 | 13,752 |
| Adjustments: | Depreciation | 7,861 | 8,338 | 8,399 | 24,406 | 23,695 |
| Adjustments: | Amortization of completed technology | 2,082 | 2,076 | 2,068 | 6,017 | 5,876 |
| Adjustments: | Amortization of other intangible assets | 3,616 | 3,563 | 4,123 | 10,730 | 12,499 |
| Adjustments: | Earnings before interest, taxes, depreciation and amortization - Continuing operations | 10,580 | -147,754 | 11,920 | -130,715 | 14,867 |
Income Statement
Quarter Ended (in thousands)
| Quarter Ended – June 30, 2026 | Quarter Ended – June 30, 2026 | Quarter Ended – March 31, 2026 | Quarter Ended – March 31, 2026 | Quarter Ended – June 30, 2025(*) | Quarter Ended – June 30, 2025(*) | ||
|---|---|---|---|---|---|---|---|
| GAAP gross profit | 72,356 | 44.9 | 62,035 | 42.8 | 66,404 | 46.2 | |
| Adjustments: | Amortization of completed technology | 2,082 | 1.3 | 2,076 | 1.4 | 2,068 | 1.4 |
| Adjustments: | Other Adjustments | 25 | 0 | ||||
| Adjustments: | Non-GAAP adjusted gross profit | 74,438 | 46.2 | 64,111 | 44.3 | 68,497 | 47.6 |
Income Statement
Nine Months Ended (in thousands)
| Nine Months Ended – June 30, 2026 | Nine Months Ended – June 30, 2026 | Nine Months Ended – June 30, 2025(*) | Nine Months Ended – June 30, 2025(*) | ||
|---|---|---|---|---|---|
| GAAP gross profit | 198,097 | 43.6 | 198,006 | 45.6 | |
| Adjustments: | Amortization of completed technology | 6,017 | 1.3 | 5,876 | 1.4 |
| Adjustments: | Transformation costs(1) | 51 | 0 | ||
| Adjustments: | Other Adjustments | 25 | 0 | ||
| Adjustments: | Non-GAAP adjusted gross profit | 204,114 | 44.9 | 203,958 | 46.9 |
Income Statement
| Sample Management Solutions – Quarter Ended – June 30, 2026 | Sample Management Solutions – Quarter Ended – June 30, 2026 | Sample Management Solutions – Quarter Ended – March 31, 2026 | Sample Management Solutions – Quarter Ended – March 31, 2026 | Sample Management Solutions – Quarter Ended – June 30, 2025(*) | Sample Management Solutions – Quarter Ended – June 30, 2025(*) | Multiomics – Quarter Ended – June 30, 2026 | Multiomics – Quarter Ended – June 30, 2026 | Multiomics – Quarter Ended – March 31, 2026 | Multiomics – Quarter Ended – March 31, 2026 | Multiomics – Quarter Ended – June 30, 2025(*) | Multiomics – Quarter Ended – June 30, 2025(*) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GAAP gross profit | 39,126 | 44.3 | 37,084 | 45.7 | 40,180 | 51.8 | 33,230 | 45.6 | 24,951 | 39.2 | 26,224 | 39.6 | |
| Adjustments: | Amortization of completed technology | 1,393 | 1.6 | 1,389 | 1.7 | 1,208 | 1.6 | 689 | 0.9 | 687 | 1.1 | 860 | 1.3 |
| Adjustments: | Other Adjustments | 25 | 0 | ||||||||||
| Adjustments: | Non-GAAP adjusted gross profit | 40,519 | 45.9 | 38,473 | 47.4 | 41,413 | 53.4 | 33,919 | 46.5 | 25,638 | 40.2 | 27,084 | 40.9 |
Income Statement
| Sample Management Solutions – Nine Months Ended – June 30, 2026 | Sample Management Solutions – Nine Months Ended – June 30, 2026 | Sample Management Solutions – Nine Months Ended – June 30, 2025(*) | Sample Management Solutions – Nine Months Ended – June 30, 2025(*) | Multiomics – Nine Months Ended – June 30, 2026 | Multiomics – Nine Months Ended – June 30, 2026 | Multiomics – Nine Months Ended – June 30, 2025(*) | Multiomics – Nine Months Ended – June 30, 2025(*) | ||
|---|---|---|---|---|---|---|---|---|---|
| GAAP gross profit | 111,993 | 44.7 | 115,471 | 48.4 | 86,104 | 42.2 | 82,535 | 42.1 | |
| Adjustments: | Amortization of completed technology | 3,958 | 1.6 | 3,296 | 1.4 | 2,059 | 1 | 2,580 | 1.3 |
| Adjustments: | Transformation costs(1) | 51 | 0 | ||||||
| Adjustments: | Other Adjustments | 25 | 0 | $— | $— | ||||
| Adjustments: | Non-GAAP adjusted gross profit | 115,951 | 46.2 | 118,843 | 49.8 | 88,163 | 43.3 | 85,115 | 43.4 |
Income Statement
| Total Segments – Quarter Ended – June 30, 2026 | Total Segments – Quarter Ended – March 31, 2026 | Total Segments – Quarter Ended – June 30, 2025(*) | Corporate – Quarter Ended – June 30, 2026 | Corporate – Quarter Ended – March 31, 2026 | Corporate – Quarter Ended – June 30, 2025(*) | Total – Quarter Ended – June 30, 2026 | Total – Quarter Ended – March 31, 2026 | Total – Quarter Ended – June 30, 2025(*) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GAAP operating loss | 2,051 | 4,505 | -6,229 | -156,699 | -6,355 | -4,178 | -165,790 | -1,850 | ||
| Adjustments: | Amortization of completed technology | 2,082 | 2,068 | 2,082 | 2,076 | 2,068 | ||||
| Adjustments: | Amortization of other intangible assets | 49 | 3,567 | 3,563 | 4,123 | 3,616 | 3,563 | 4,123 |
Income Statement
| Total Segments – Nine Months Ended – June 30, 2026 | Total Segments – Nine Months Ended – June 30, 2025(*) | Corporate – Nine Months Ended – June 30, 2026 | Corporate – Nine Months Ended – June 30, 2025(*) | Total – Nine Months Ended – June 30, 2026 | Total – Nine Months Ended – June 30, 2025(*) | ||
|---|---|---|---|---|---|---|---|
| GAAP operating loss | -8,355 | -2,276 | -168,850 | -26,469 | -177,205 | -28,745 | |
| Adjustments: | Amortization of completed technology | 6,017 | 5,876 | 6,017 | 5,876 | ||
| Adjustments: | Amortization of other intangible assets | 49 | 10,681 | 12,499 | 10,730 | 12,499 | |
| Adjustments: | Transformation costs(1) | 168 | 2,877 | 1,745 | 6,894 | 1,913 | 9,771 |
| Adjustments: | Restructuring charges | 3,078 | 4,765 | 3,078 | 4,765 | ||
| Adjustments: | Impairment of goodwill and intangible assets(2) | 149,083 | 149,083 | ||||
| Adjustments: | Merger and acquisition costs(3) | 204 | 4,232 | 2,316 | 4,436 | 2,316 | |
| Adjustments: | Purchase accounting and other adjustments | 175 | 40 | -5 | 175 | 35 | |
| Adjustments: | Non-GAAP adjusted operating income (loss) | -1,742 | 6,517 | -31 | -1,773 | 6,517 |
Balance Sheet
(In thousands, except share and per share data)
| June 30, 2026 | September 30, 2025 | ||
|---|---|---|---|
| Current assets | Cash and cash equivalents | 189,654 | 279,783 |
| Current assets | Short-term marketable securities | 136,143 | 61,137 |
| Current assets | Accounts receivable, net of allowance for expected credit losses ($3,953 and $4,649, respectively) | 143,675 | 142,181 |
| Current assets | Inventories | 79,082 | 74,956 |
| Current assets | Short-term restricted cash | 2,414 | 2,359 |
| Current assets | Refundable income taxes | 5,846 | 9,728 |
| Current assets | Prepaid expenses and other current assets | 53,150 | 64,660 |
| Current assets | Current assets held for sale | 71,387 | 73,535 |
| Current assets | Total current assets | 681,351 | 708,339 |
| Current assets | Property, plant and equipment, net | 172,427 | 153,954 |
| Current assets | Long-term marketable securities | 196,087 | 201,585 |
| Current assets | Long-term deferred tax assets | 494 | 726 |
| Current assets | Operating lease right-of-use assets | 61,421 | 54,048 |
| Current assets | Goodwill | 547,457 | 702,395 |
| Current assets | Intangible assets, net | 85,688 | 101,814 |
| Current assets | Long-term income taxes receivable | 45,600 | 45,600 |
| Current assets | Other assets | 8,997 | 6,115 |
| Current assets | Noncurrent assets held for sale | 76,689 | 85,006 |
| Current assets | Total assets | 1,876,211 | 2,059,582 |
| Current liabilities | Accounts payable | 39,381 | 37,722 |
| Current liabilities | Deferred revenue | 36,041 | 31,569 |
| Current liabilities | Derivative liability | 28,435 | 33,420 |
| Current liabilities | Accrued warranty and retrofit costs | 4,047 | 4,713 |
| Current liabilities | Accrued compensation and benefits | 30,965 | 35,799 |
| Current liabilities | Customer deposits | 35,355 | 26,499 |
| Current liabilities | Accrued income taxes payable | 6,775 | 9,416 |
| Current liabilities | Deposit received for the sale of B Medical Systems business | 28,000 | |
| Current liabilities | Accrued expenses and other current liabilities | 34,249 | 30,268 |
| Current liabilities | Current liabilities held for sale | 29,326 | 28,268 |
| Current liabilities | Total current liabilities | 272,574 | 237,674 |
| Current liabilities | Long-term deferred tax liabilities | 15,836 | 18,245 |
| Current liabilities | Long-term operating lease liabilities | 53,967 | 51,244 |
| Current liabilities | Other long-term liabilities | 10,725 | 11,142 |
| Current liabilities | Noncurrent liabilities held for sale | 12,980 | 14,291 |
| Current liabilities | Total liabilities | 366,082 | 332,596 |
| Stockholders' equity | Common stock, $0.01 par value - 125,000,000 shares authorized, 57,226,616 shares issued and 43,764,747 shares outstanding at June 30, 2026; 59,320,848 shares issued and 45,858,979 shares outstanding at September 30, 2025 | 572 | 594 |
| Stockholders' equity | Additional paid-in capital | 493,071 | 529,605 |
| Stockholders' equity | Accumulated other comprehensive loss | -28,740 | -22,213 |
| Stockholders' equity | Treasury stock, at cost - 13,461,869 shares at June 30, 2026 and September 30, 2025 | -200,956 | -200,956 |
| Stockholders' equity | Retained earnings | 1,246,182 | 1,419,956 |
| Stockholders' equity | Total stockholders' equity | 1,510,129 | 1,726,986 |
| Stockholders' equity | Total liabilities and stockholders' equity | 1,876,211 | 2,059,582 |
Cash Flow
Nine Months Ended June 30, — (In thousands) (in thousands)
| Nine Months Ended June 30, – 2026 | Nine Months Ended June 30, – 2025 | ||
|---|---|---|---|
| Cash flows from operating activities | Net loss | -173,774 | -106,640 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Depreciation and amortization | 41,230 | 46,775 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Impairment of goodwill and intangible assets | 149,083 | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Non-cash gain from settlement of preexisting contractual relationship | -3,858 | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Loss on assets held for sale | 9,491 | 92,706 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Inventory write-downs and other non-cash items | 1,301 | 3,866 |
Full release
Azenta expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.
AZENTA INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis and Investor Relations ir@azenta.com
Maria Isabel Cuartas
Manager Investor Relations ir@azenta.com⁴